FAQ: Frequently Asked Questions
Your Nozin advisor will partner with you to perform a site-specific analysis of your current environment, identify areas of potential infection risk that can be addressed by Nozin programs, costs, and potential savings as well as participate in or lead discussions with decision makers.
Nozin advisors will fully support your implementation process with a step-by-step guide and will assist in creating high-impact clinical protocols outlining the use of the Nozin® Nasal Sanitizer® antiseptic. Learn more about Nozin programs here.
Yes. More than 15 studies including peer-reviewed research and independently conducted studies are available for review. To access clinical outcomes using Nozin® Nasal Sanitizer® antiseptic, click here
Nozin® Nasal Sanitizer® is a non-prescription, broad spectrum antiseptic with demonstrated microbial killing activity when topically applied to the nares. The patented Nozin® Nasal Sanitizer® formula, Nozaseptin™, combines the safe, proven, antiseptic power of ethyl alcohol with the emollient, antioxidant benefits of natural oils.
In testing by independent FDA registered laboratories, Nozin® Nasal Sanitizer® was shown on application in vitro to kill 99.99+% of a broad spectrum of pathogenic organisms. Nozin® Nasal Sanitizer® has also been shown to decrease S. aureus and other nasal bacterial carriage (see in vitro studies). Unlike an antibiotic, Nozin® Nasal Sanitizer® does not promote antibiotic resistance as it utilizes the non-selective antiseptic action of ethanol. It is well tolerated by users as it has a pleasant citrus scent and is highly moisturizing to the nasal opening.
Nozin® Nasal Sanitizer® is available in two presentations, the bottle and the POPSwab® ampule. To learn more about product information, ingredients and to view the drug facts click here.
Nozin Nasal Sanitizer® can be used throughout a healthcare facility and hospital to reduce nasal carriage, enhance hand hygiene efforts and lower the risk of nasal pathogen transmission.
A comprehensive implementation could include:
Patient use:
- high risk areas such as Emergency Room and ICU
- pre and post procedure measures
- facility/hospital-wide
Staff use:
- care areas for patients with high susceptibility for infection such as oncology, transplant, NICU
- areas of potential high risk for staff acquisition, such as Emergency/Trauma, high contagion/pathogen burden
- facility/hospital-wide
Visitors use:
- facility/high risk areas
Learn about the 360™ Program and Professional Solutions your facility.
A number of factors support Nozin® Nasal Sanitizer® use by health care workers (HCW). Studies show that 30% of the population has S. aureus colonization in the nares. Chances are good that your facility’s HCWs have S. aureus colonization at that percentage. In addition, transient nasal inoculation by S. aureus or other potential pathogens may occur through contact during the work day. All of these bacteria are then positioned for transfer to patients and other personnel. High risk areas like the ICU, ER and surgical floors would be recommended targets for the use of Nasal Sanitizer® to help reduce risk of infection.
As nose touching frequently compromises hand hygiene, Nasal Sanitizer® can be used to complement hand washing and hand sanitizer use. HCWs can regularly use Nasal Sanitizer® antiseptic as it gives them an extra layer of protection in addition to hand hygiene. The application is pleasant, moisturizing and, importantly, bacteria will not build antibiotic resistance to this non-antibiotic product.
Pregnant women should consult their physician regarding use of Nozin® Nasal Sanitizer®.
Yes, the Popswab® ampules are available for personal use in the online shop at nozin.com/consumer-store.
For your facility, click here. to receive a custom analysis.
Yes. Nozin® Nasal Sanitizer® has a 12-hour persistence and is specifically formulated for regular daily use. The product complies with Food and Drug Administration (FDA) regulations for over the counter (OTC) drugs as an antiseptic. Ethanol, the active ingredient in Nasal Sanitizer®, is classified as GRASE (generally recognized as safe and effective) when used as directed.
It has been shown that alcohol-based topical antiseptics can be less irritating than soap and water and Nasal Sanitizer® has been specifically shown to be safe in dermal toxicity and skin irritation studies.
Yes. Nasal decolonization is an important topic which is covered in the white paper "Emerging Strategies on Achieving Nasal Decolonization for Reducing Hospital Acquired Infections." A wealth of medical literature demonstrates that nasal carriage plays a major role in health care-associated Infections (HAI )and surgical site infections (SSI) and that infection prevention protocols which include nasal decolonization can result in significant reductions in infection.
Nasal decolonization is a promising opportunity for infection control and remains under-utilized. Hand to nose contact occurs about every 4 minutes for everyone, often compromising hand hygiene and risking contamination. 80% of SSI pathogens’ DNA can be tracked to the patient’s own nose. On the basis of new reimbursement policies and significant recent studies, facilities and hospitals recognize the imperative of patient nasal carriage reduction programs Research also indicates that including nasal hygiene for health care workers (HCW) may be beneficial.
Click here to view additional research surrounding nasal decolonization and Nozin® Nasal Sanitizer®.
Children under 12 years old should be supervised in use. A physician should be consulted for use on children under 2.
The cost of implementing varies by facility. Click here to receive a custom analysis and pricing for your facility.
Global Life Technologies Corp. owns all Nozin brand products including Nozin® Nasal Sanitizer® antiseptic. Global Life Technologies Corp. follows a mission to improve the quality of life for people by introducing unique and effective healthcare products based on innovative technologies.
Backed by over 15 years of research, supported by NIH grants, and successful clinical trials, Nozin products are designed to improve care, lower infection risk, and reduce healthcare costs.
Made in the USA, Nozin products are trusted in use by thousands of clinicians and infection control professionals.
Studies show that ~30% of the population has S. aureus colonization in the nares and ~3% have MRSA. Providing patients Nozin® Nasal Sanitizer® upon hospital admission can help reduce the risk of bringing these potential pathogens into the health care facility and contributing to the environmental bacterial burden and colonization pressure that results.
